AR074053A1 - Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), y composiciones farmaceuticas que los contienen - Google Patents
Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), y composiciones farmaceuticas que los contienenInfo
- Publication number
- AR074053A1 AR074053A1 ARP090104043A ARP090104043A AR074053A1 AR 074053 A1 AR074053 A1 AR 074053A1 AR P090104043 A ARP090104043 A AR P090104043A AR P090104043 A ARP090104043 A AR P090104043A AR 074053 A1 AR074053 A1 AR 074053A1
- Authority
- AR
- Argentina
- Prior art keywords
- anilina
- cycline
- sulfoximine
- cdk
- inhibitors
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Reivindicacion 1: Un compuesto, caracterizado porque es de la formula general (1) en donde X representa -O- o -NH- y R1 representa un grupo metilo, etilo, propilo o isopropilo, y R2 y R3 representan, de manera independiente entre sí, hidrogeno, un grupo metilo o un grupo etilo, y R4 representa un grupo C1-6-alquilo o un anillo C3-7-cicloalquilo, y sales, diastereomeros y enantiomeros de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08167113A EP2179991A1 (de) | 2008-10-21 | 2008-10-21 | Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074053A1 true AR074053A1 (es) | 2010-12-22 |
Family
ID=40282208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104043A AR074053A1 (es) | 2008-10-21 | 2009-10-21 | Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), y composiciones farmaceuticas que los contienen |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US8735412B2 (es) |
| EP (2) | EP2179991A1 (es) |
| JP (1) | JP5564054B2 (es) |
| KR (1) | KR20110069115A (es) |
| CN (1) | CN102197029B (es) |
| AR (1) | AR074053A1 (es) |
| AU (1) | AU2009306733C1 (es) |
| BR (1) | BRPI0920112A2 (es) |
| CA (1) | CA2739739C (es) |
| CO (1) | CO6361926A2 (es) |
| CR (1) | CR20110210A (es) |
| CU (1) | CU24052B1 (es) |
| CY (1) | CY1115590T1 (es) |
| DK (1) | DK2350026T3 (es) |
| DO (1) | DOP2011000107A (es) |
| EA (1) | EA019230B1 (es) |
| EC (1) | ECSP11010992A (es) |
| ES (1) | ES2499028T3 (es) |
| HN (1) | HN2011001019A (es) |
| HR (1) | HRP20140830T1 (es) |
| IL (1) | IL211713A (es) |
| MA (1) | MA32723B1 (es) |
| MX (1) | MX2011004238A (es) |
| MY (1) | MY155230A (es) |
| NZ (1) | NZ592314A (es) |
| PA (1) | PA8846201A1 (es) |
| PE (1) | PE20110546A1 (es) |
| PL (1) | PL2350026T3 (es) |
| PT (1) | PT2350026E (es) |
| RS (1) | RS53523B1 (es) |
| SA (1) | SA109300632B1 (es) |
| SI (1) | SI2350026T1 (es) |
| TN (1) | TN2011000199A1 (es) |
| TW (2) | TWI458716B (es) |
| UA (1) | UA103500C2 (es) |
| UY (1) | UY32190A (es) |
| WO (1) | WO2010046035A1 (es) |
| ZA (1) | ZA201103727B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8729265B2 (en) | 2009-08-14 | 2014-05-20 | Boehringer Ingelheim International Gmbh | Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives |
| US8933227B2 (en) | 2009-08-14 | 2015-01-13 | Boehringer Ingelheim International Gmbh | Selective synthesis of functionalized pyrimidines |
| DE102010014427A1 (de) | 2010-04-01 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Kombinationen neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren |
| DE102010014426A1 (de) * | 2010-04-01 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren |
| DE102010046720A1 (de) * | 2010-09-23 | 2012-03-29 | Bayer Schering Pharma Aktiengesellschaft | Verfahren zur Herstellung von pan-CDK-Inhibitoren der Formel (l), sowie Intermediate der Herstellung |
| TWI555737B (zh) * | 2011-05-24 | 2016-11-01 | 拜耳知識產權公司 | 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺 |
| DE102011080992A1 (de) * | 2011-08-16 | 2013-02-21 | Bayer Pharma AG | Verwendung von MAD2L2 als Stratifikationsmarker bei der Behandlung von Brusttumoren mit neuen pan-CDK-Inhibitoren |
| DE102011080991A1 (de) * | 2011-08-16 | 2013-02-21 | Bayer Pharma AG | Verwendung von CCNE2 als Stratifikationsmarker bei der Behandlung von Brusttumoren mit neuen pan-CDK-Inhibitoren |
| CN103930399B (zh) | 2011-09-16 | 2016-03-16 | 拜耳知识产权有限责任公司 | 包含亚氨基亚磺酰基的二取代的5-氟嘧啶衍生物 |
| US20150051232A1 (en) * | 2012-03-21 | 2015-02-19 | Bayer Intellectual Property Gmbh | Use of (rs)-s-cyclopropyl-s-(4--5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treating specific tumours |
| CN107001341B (zh) * | 2014-10-16 | 2020-08-07 | 拜耳医药股份有限公司 | 含有磺亚胺基的氟化苯并呋喃基-嘧啶衍生物 |
| JP2022500388A (ja) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4029650A1 (de) | 1990-09-19 | 1992-03-26 | Hoechst Ag | 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide |
| ATE311884T1 (de) | 1997-07-12 | 2005-12-15 | Cancer Rec Tech Ltd | Cyclin-abhängige-kinase inhibierende purinderivate |
| US6440965B1 (en) | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
| EP1107958B1 (en) | 1998-08-29 | 2006-08-16 | AstraZeneca AB | Pyrimidine compounds |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
| RS94703A (sr) | 2001-05-29 | 2007-02-05 | Schering Aktiengesellschaft, | Cdk-inhibirajući pirimidini, njihovo dobijanje i primena kao sredstva za lečenje |
| AU2003212282A1 (en) | 2002-03-11 | 2003-09-22 | Schering Aktiengesellschaft | Cdk inhibiting 2-heteroaryl pyrimidine, the production thereof, and use thereof as a medicament |
| EA200500721A1 (ru) | 2002-11-28 | 2005-12-29 | Шеринг Акциенгезельшафт | Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств |
| DE10349423A1 (de) * | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| JP2008514571A (ja) * | 2004-09-29 | 2008-05-08 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 細胞周期−キナーゼまたはレセプター−チロシン−キナーゼインヒビターとしての置換２−置換アニリノピリミジン類、それらの製造および薬剤としての使用 |
| DE102005062742A1 (de) | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Ag | Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel |
| DE102006027156A1 (de) | 2006-06-08 | 2007-12-13 | Bayer Schering Pharma Ag | Sulfimide als Proteinkinaseinhibitoren |
| EP2179992A1 (de) * | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
-
2008
- 2008-10-21 EP EP08167113A patent/EP2179991A1/de not_active Withdrawn
-
2009
- 2009-10-09 CA CA2739739A patent/CA2739739C/en not_active Expired - Fee Related
- 2009-10-09 KR KR1020117009024A patent/KR20110069115A/ko not_active Abandoned
- 2009-10-09 PT PT97788749T patent/PT2350026E/pt unknown
- 2009-10-09 EA EA201100623A patent/EA019230B1/ru not_active IP Right Cessation
- 2009-10-09 ES ES09778874.9T patent/ES2499028T3/es active Active
- 2009-10-09 US US13/125,066 patent/US8735412B2/en not_active Expired - Fee Related
- 2009-10-09 DK DK09778874.9T patent/DK2350026T3/da active
- 2009-10-09 AU AU2009306733A patent/AU2009306733C1/en not_active Ceased
- 2009-10-09 MY MYPI2011001632A patent/MY155230A/en unknown
- 2009-10-09 PE PE2011000917A patent/PE20110546A1/es not_active Application Discontinuation
- 2009-10-09 JP JP2011532519A patent/JP5564054B2/ja not_active Expired - Fee Related
- 2009-10-09 WO PCT/EP2009/007247 patent/WO2010046035A1/de not_active Ceased
- 2009-10-09 HR HRP20140830AT patent/HRP20140830T1/hr unknown
- 2009-10-09 NZ NZ592314A patent/NZ592314A/xx not_active IP Right Cessation
- 2009-10-09 UA UAA201106183A patent/UA103500C2/uk unknown
- 2009-10-09 BR BRPI0920112A patent/BRPI0920112A2/pt not_active IP Right Cessation
- 2009-10-09 SI SI200931004T patent/SI2350026T1/sl unknown
- 2009-10-09 RS RSP20140466 patent/RS53523B1/sr unknown
- 2009-10-09 PL PL09778874T patent/PL2350026T3/pl unknown
- 2009-10-09 EP EP09778874.9A patent/EP2350026B1/de active Active
- 2009-10-09 CN CN200980141978.7A patent/CN102197029B/zh not_active Expired - Fee Related
- 2009-10-09 MX MX2011004238A patent/MX2011004238A/es active IP Right Grant
- 2009-10-19 PA PA20098846201A patent/PA8846201A1/es unknown
- 2009-10-20 UY UY0001032190A patent/UY32190A/es not_active Application Discontinuation
- 2009-10-20 SA SA109300632A patent/SA109300632B1/ar unknown
- 2009-10-21 AR ARP090104043A patent/AR074053A1/es not_active Application Discontinuation
- 2009-10-21 TW TW098135674A patent/TWI458716B/zh not_active IP Right Cessation
- 2009-10-21 TW TW103126302A patent/TWI496774B/zh not_active IP Right Cessation
-
2011
- 2011-03-14 IL IL211713A patent/IL211713A/en not_active IP Right Cessation
- 2011-04-15 HN HN2011001019A patent/HN2011001019A/es unknown
- 2011-04-20 DO DO2011000107A patent/DOP2011000107A/es unknown
- 2011-04-20 EC EC2011010992A patent/ECSP11010992A/es unknown
- 2011-04-20 TN TN2011000199A patent/TN2011000199A1/fr unknown
- 2011-04-20 CU CU2011000088A patent/CU24052B1/es active IP Right Grant
- 2011-04-20 CO CO11049624A patent/CO6361926A2/es active IP Right Grant
- 2011-04-20 MA MA33786A patent/MA32723B1/fr unknown
- 2011-04-25 CR CR20110210A patent/CR20110210A/es unknown
- 2011-05-20 ZA ZA2011/03727A patent/ZA201103727B/en unknown
-
2014
- 2014-09-05 CY CY20141100717T patent/CY1115590T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR074053A1 (es) | Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), y composiciones farmaceuticas que los contienen | |
| CR9602A (es) | Nuevos derivados de 2,4-dianilinpirimidinas, su preparacion, como medicamentos, composiciones farmaceuticas y particularmente como inhibidores de ikk | |
| UY30498A1 (es) | Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones | |
| AR063988A1 (es) | Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| GT200600134A (es) | Compuestos novedosos de derivados de aminosulfonilo | |
| CU24030B1 (es) | Nuevos derivados de benzotiadiazepinas, su procedimiento de preparación y composiciones farmacéuticas que los contienen | |
| HN2007000267A (es) | Compuestos de 4-metil piridopirimidinoma | |
| CR10148A (es) | Derivados de las benzamidas y heteroarenos | |
| UY30105A1 (es) | Derivados nuevos azufrados de urea cíclica, su preparación y su utilización farmacéutica como inhibidores de quinasas. | |
| ECSP088377A (es) | Derivados de carbamoilbenzotriazol como inhibidores de lipasas y fosfolipasas | |
| UY31712A1 (es) | Nuevos derivados de diosmetina, su procedimiento de preparacion y las composiciones farmacéuticas que los contienen | |
| NI200900147A (es) | Nuevos derivados tricíclicos su procedimiento de preparación y las composiciones farmacéuticas que los contienen. | |
| AR077510A1 (es) | Derivados de dihidroindolonas, su procedimiento de preparacion y las com-posiciones farmaceuticas que los contienen | |
| DOP2006000045A (es) | Derivados del (1,5-difenil-1h-pirazol-3-il oxadiazol, su preparacion y su aplicacion en terapeutica | |
| MX2011004088A (es) | Derivado de anillo fusionado y su aplicacion medica. | |
| CR8572A (es) | Derivados de oxidiazolona como agonistas de la actividad de delta ppar | |
| AR059031A1 (es) | Combinacion de derivados de triazina e inhibidores de la hmg- coa reductasa | |
| AR076222A1 (es) | Derivados 2-hidroxietil-1h-quinolin-ona y sus analogos azaisotericos con actividad antibacteriana y composiciones farmaceuticas que los contienen | |
| AR061740A1 (es) | Nuevos derivados naftalenicos, su procedimiento de praparacion y las composiciones farmaceuticas que los contienen | |
| AR061741A1 (es) | Nuevos derivados naftalenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR079267A1 (es) | Derivados del tipo hexahidrociclopenta(b)pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| UY29804A1 (es) | Quinolinas de alquilnitrilo | |
| UY30001A1 (es) | Alquilsulfonamida quinolinas | |
| GT201300067A (es) | Nuevos derivados dihidrobenzoxatiazepinas. su procedimiento de preparacion y las composiciones farmaceuticas que los | |
| UY33927A (es) | Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FB | Suspension of granting procedure |